Real‐time cell cycle imaging during melanoma growth, invasion, and drug response

Solid cancers are composed of heterogeneous zones containing proliferating and quiescent cells. Despite considerable insight into the molecular mechanisms underlying aberrant cell cycle progression, there is limited understanding of the relationship between the cell cycle on the one side, and melanoma cell motility, invasion, and drug sensitivity on the other side. Utilizing the fluorescent ubiquitination‐based cell cycle indicator (FUCCI) to longitudinally monitor proliferation and migration of melanoma cells in 3D culture and in vivo, we found that invading melanoma cells cycle actively, while G1‐arrested cells showed decreased invasion. Melanoma cells in a hypoxic environment or treated with mitogen‐activated protein kinase pathway inhibitors remained G1‐arrested for extended periods of time, with proliferation and invasion resuming after re‐exposure to a more favorable environment. We challenge the idea that the invasive and proliferative capacity of melanoma cells are mutually exclusive and further demonstrate that a reversibly G1‐arrested subpopulation survives in the presence of targeted therapies.

[1]  U. Schumacher,et al.  Melanoma never says die , 2014, Experimental dermatology.

[2]  P. Gimotty,et al.  MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines , 2014, Oncogene.

[3]  Nikolas K. Haass,et al.  Modeling Melanoma In Vitro and In Vivo , 2013, Healthcare.

[4]  S. Pavey,et al.  DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma , 2013, Pigment cell & melanoma research.

[5]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[6]  R. Dummer,et al.  Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. , 2013, The Journal of investigative dermatology.

[7]  L. Ng,et al.  A quantitative approach to histopathological dissection of elastin‐related disorders using multiphoton microscopy , 2013, The British journal of dermatology.

[8]  N. Haass,et al.  Melanoma's connections to the tumour microenvironment. , 2013, Pathology.

[9]  R. Abraham,et al.  Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies , 2012, Pigment cell & melanoma research.

[10]  Junji Fukuda,et al.  An oxygen-permeable spheroid culture system for the prevention of central hypoxia and necrosis of spheroids. , 2012, Biomaterials.

[11]  L. Chin,et al.  Melanoma: from mutations to medicine. , 2012, Genes & development.

[12]  L. Ng,et al.  Intravital multiphoton imaging of immune responses in the mouse ear skin , 2012, Nature Protocols.

[13]  P. Hersey,et al.  Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737 , 2011, Clinical Cancer Research.

[14]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Dummer,et al.  A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status , 2011, Pigment cell & melanoma research.

[16]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[17]  M. Herlyn,et al.  PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas , 2010, Pigment cell & melanoma research.

[18]  K. Hoek,et al.  Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.

[19]  M. Shackleton Moving targets that drive cancer progression. , 2010, The New England journal of medicine.

[20]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[21]  A. Santiago-Walker,et al.  Melanocytes: From Morphology to Application , 2009, Skin Pharmacology and Physiology.

[22]  M. Herlyn,et al.  Melanoma and the tumor microenvironment , 2008, Current oncology reports.

[23]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[24]  Atsushi Miyawaki,et al.  Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression , 2008, Cell.

[25]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[26]  M. Herlyn,et al.  The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.

[27]  M. Herlyn,et al.  In vitro three-dimensional tumor microenvironment models for anticancer drug discovery , 2008, Expert opinion on drug discovery.

[28]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[29]  J. McNamara Cancer Stem Cells , 2007, Methods in Molecular Biology.

[30]  K. Flaherty,et al.  Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels , 2007, British Journal of Cancer.

[31]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[32]  Lai Guan Ng,et al.  Random migration precedes stable target cell interactions of tumor-infiltrating T cells , 2006, The Journal of experimental medicine.

[33]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[34]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[35]  Keith T Flaherty,et al.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.

[36]  R. Scolyer,et al.  Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma , 2005, Journal of Clinical Pathology.

[37]  Eric Brown,et al.  Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. , 2005, The American journal of pathology.

[38]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[39]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[40]  R. Durand Use of Hoechst 33342 for cell selection from multicell systems. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[42]  M. Herlyn,et al.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. , 2012, Advances in pharmacology.

[43]  P. Friedl,et al.  Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. , 2012, Trends in molecular medicine.

[44]  K. Flaherty,et al.  An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.

[45]  K. Groebe,et al.  Distributions of oxygen, nutrient, and metabolic waste concentrations in multicellular spheroids and their dependence on spheroid parameters , 2004, European Biophysics Journal.